SCHEMBL18352131

SCHEMBL18352131

CNC(=O)CO/N=C/c1ccc(F)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.70
ALDH1A1 P00352 3/20 0.70
KDM4E B2RXH2 2/20 0.70
LMNA P02545 6/20 0.60
RECQL P46063 1/20 0.60
POLB P06746 2/20 0.59
HTT P42858 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
ATM Q13315 1/20 0.53
MAPT P10636 3/20 0.52
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
GAA P10253 1/20 0.48
CYP1A2 P05177 1/20 0.47
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PLA2G7 Q13093 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17831026 1.00 SMN1; SMN2 (0.70) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL15032082 0.86 SMN1; SMN2 (0.72) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL23992348 0.84 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL13025225 0.83 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL12705075 0.83 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL670003 0.81 PLA2G7 (0.54) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL670004 0.81 PLA2G7 (0.54) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL14077931 0.80 PLA2G7 (0.53) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL19303336 0.79 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1KDM4ELMNARECQL
SCHEMBL19296378 0.79 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1KDM4ELMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311636-B2 Radiotracer compositions and methods GE HEALTHCARE LIMITED (GB) 2022-04-26 US disclosed
US-20190275182-A1 RADIOTRACER COMPOSITIONS AND METHODS GE HEALTHCARE LIMITED (GB) 2019-09-12 US disclosed
US-10300156-B2 Radiotracer compositions and methods GE HEALTHCARE LIMITED (GB) 2019-05-28 US disclosed
US-9533059-B2 Peptide radiotracer compositions GE HEALTHCARE LIMITED (GB) 2017-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190275182-A1 RADIOTRACER COMPOSITIONS AND METHODS MET, METTL14, MEN1 SMN1; SMN2 3898/4885ALDH1A1 4112/4885KDM4E 2261/4885
US-10300156-B2 Radiotracer compositions and methods MET, METTL14, MEN1 SMN1; SMN2 3898/4885ALDH1A1 4112/4885KDM4E 2261/4885
US-11311636-B2 Radiotracer compositions and methods MET, METTL14, MEN1 SMN1; SMN2 3898/4885ALDH1A1 4112/4885KDM4E 2261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.